Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Search

Our Leadership

Meet Our Leadership Team

Janssen is dedicated to addressing and solving some of the most important unmet medical needs of our time in Oncology, Immunology, NeuroscienceInfectious Diseases & Vaccines, Cardiovascular & Metabolism and Pulmonary Hypertension. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world. We recognize the impact of serious conditions on people's lives, and we aim to empower people through disease awareness, education and access to quality care.

As part of the Johnson & Johnson Family of Companies, the world's most comprehensive and broadly based manufacturer of healthcare products, we believe that we have an opportunity and an obligation to make a significant positive impact in the world by addressing the most serious unmet medical needs of our time.

Here is our leadership team that guides Janssen.

JOAQUIN DUATO

VICE CHAIRMAN OF THE EXECUTIVE COMMITTEE
JOHNSON & JOHNSON

Joaquin Duato is a globally-experienced, values-driven health care business leader and currently Vice Chairman of the Executive Committee of Johnson & Johnson, the world’s premier healthcare company. Joaquin is responsible for the Company’s Pharmaceuticals and Consumer sectors, as well as Supply Chain, Information Technology, Global Services, and the Health and Wellness groups. He is a respected industry leader and is the immediate past Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Joaquin played an instrumental role in leading the turnaround of the Johnson & Johnson Pharmaceuticals sector. A 28-year veteran of the Company, Joaquin was named Company Group Chairman of the Americas in 2009. He then continued leading the global transformation upon his appointment to his most recent role as Executive Vice President and Worldwide Chairman, Pharmaceuticals in 2011. During that time, the sector grew into what is today the fourth-largest innovative pharmaceutical company globally. The results are clear: with 17 new products launched since 2011 and up to 10 potential billion-dollar medicines expected to be launched and/or filed before 2021, the Johnson & Johnson Pharmaceuticals sector is poised to extend its track record of seven years of above-market growth.

As a dual citizen of Spain and the United States with extensive experience living and working on-the-ground on multiple continents, Joaquin brings a unique international perspective to his work. His global experience has given him an appreciation for the value of diversity of thought and opinions, which he brings to bear externally as a member of the Tsinghua University SPS Advisory Board, and internally as the Executive Sponsor of the African American Leadership Council. His commitment to nurturing a culture of diversity was recognized in 2017 by the Healthcare Businesswomen’s Association (HBA) when he was named 2017 Honorable Mentor.

Joaquin also has a passion for learning, with an undergraduate degree in economics and business, a Master of Business Administration (MBA) degree from ESADE Business School in Barcelona, Spain, and a Master of International Management degree from Thunderbird in Phoenix, Arizona. He is a champion of improving access to both health literacy and education more broadly and recently completed his term as Board Member of the international charity, Save the Children. In addition, he mentors MBA candidates at universities around the world and speaks regularly on leadership in pharmaceuticals at industry forums and academic institutions.

Joaquin Duato

Vice Chairman of the Executive Committee
Johnson & Johnson

PAUL STOFFELS, M.D.

Vice Chairman of the Executive Committee
Chief Scientific Officer
Johnson & Johnson

Paul Stoffels is a visionary leader who inspires and drives transformational innovation to bring years of life and quality of life to millions of people around the world.

Paul spearheads the Johnson & Johnson research pipeline by leading teams across all our sectors to set the company-wide innovation agenda, discovering and developing transformational healthcare solutions. He also is responsible for the safety of all products of the Johnson & Johnson Family of Companies worldwide, and steers the company’s global public health strategy to make innovative medicines and technologies accessible in the world’s most vulnerable communities and resource-poor settings.

Paul’s commitment to fueling innovation and finding the best science, wherever it exists, is the driving force behind the launch of Johnson & Johnson Innovation in 2013, which he now leads to fuel innovative science and technology through strategic partnerships, licensing and acquisitions. Paul also oversees JJDC, the oldest corporate venture fund in the life science industry.

Previously, in his role as Worldwide Chairman, Pharmaceuticals, Paul led the transformation of the pharmaceutical research and development pipeline of Janssen Pharmaceutical Companies of Johnson & Johnson, driving a fundamental shift in the R&D paradigm that is now a model in the industry for productivity and innovation. Under his leadership, Janssen rejuvenated its pipeline, launching multiple new medicines and making a difference for people all over the world.

Prior to this, Paul held various R&D leadership roles within the pharmaceutical sector of Johnson & Johnson. He joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and as Chairman of Tibotec, and led the development of a number of breakthrough products for the treatment of HIV that helped to transform this devastating disease from a death sentence to a chronic and treatable condition.

Paul studied medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.

Paul Stoffels, M.D.

Vice Chairman of the Executive Committee
Chief Scientific Officer
Johnson & Johnson

JENNIFER TAUBERT

Executive Vice President
Worldwide Chairman, Pharmaceuticals
Johnson & Johnson

Jennifer Taubert is Executive Vice President, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson, the world’s premier healthcare company and fourth-largest innovative pharmaceutical business. She is a member of the Corporation’s Management Committee and leads the Pharmaceuticals Group Operating Committee.

Jennifer has been a leader in shaping Janssen’s global strategy of transformational medical innovation, successfully bringing to market critical new medicines that significantly improve the lives of patients living with cancer, immune-related diseases, heart disease and diabetes, infectious diseases including HIV, pulmonary hypertension and serious mental illness. Under her leadership Janssen has become one of the largest and fastest-growing pharmaceutical companies and a significant contributor to Johnson & Johnson growth. Jennifer is also recognized as a champion of diversity and inclusion, which she sees as critical to insight, innovation and business success.

In 2005, Jennifer joined Johnson & Johnson to lead global commercial strategy for Internal Medicine and Early Development for the Pharmaceuticals Group. Later, as President, Internal Medicine, she built a powerhouse new franchise in the cardiovascular and metabolic disease. Prior to joining Johnson & Johnson, Jennifer spent 18 years in positions of increasing scope and responsibility at Merck and Allergan.

Jennifer was named to Fortune magazine’s “Most Powerful Women” list in 2016, 2017 and 2018, and received the National Association for Female Executives’ 2017 “Woman of Achievement” award. In addition to her leadership at Johnson & Johnson, Jennifer represents Johnson & Johnson on the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations. She is also a member of the National Academy of Medicine Leadership Consortium for Value and Science-Driven Healthcare, and at the global level, Jennifer represents Johnson & Johnson on the Executive Committee of the International Section of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Jennifer received a Bachelor’s degree in Pharmacology from the University of California, Santa Barbara and a Master’s of Business Administration from the Anderson Graduate School of Management, University of California, Los Angeles.

Jennifer Taubert

Executive Vice President
Worldwide Chairman, Pharmaceuticals
Johnson & Johnson

PETE BATESKO

VICE PRESIDENT, GROUP FINANCE, PHARMACEUTICALS

Pete Batesko is Vice President, Group Finance for the Pharmaceuticals Group of Johnson & Johnson.  In this position, Pete reports directly to Johnson & Johnson’s Chief Financial Officer, Dominic Caruso, and provides finance leadership to the Pharmaceuticals Group, supporting Joaquin Duato and Paul Stoffels, as a member of the Group Operating Committee. He assumed this position on August 1, 2016.

Prior to taking this position, Pete served as Vice President, Group Finance and played a critical leadership role in the restructuring and transformation of our Medical Device Group.  Prior to this role, in June 2012, Pete was appointed Vice President, Group Finance for the DePuy Synthes Companies of Johnson & Johnson, where he managed all financial aspects of the Orthopaedic business worldwide and was a member of the Group Operating Committee.

From 2006 to 2012, Pete served as the Worldwide Vice President and Chief Financial Officer for DePuy Orthopaedics, Inc. In that role, he assisted with the acquisition of Synthes and the creation of the world’s most comprehensive orthopaedic and neurological company. From 2003-2006, Pete was the Vice President of Finance and Chief Financial Officer for Ortho Biotech Products, L.P. During that tenure, he oversaw all financial areas including health care compliance, process excellence and was part of the team that returned PROCRIT® to growth.

Pete has 35 years of Johnson & Johnson experience, beginning his career in 1981 as an auditor at headquarters in New Brunswick, New Jersey. From 1995 to 2003, he worked for Ortho-McNeil Pharmaceutical, Inc. as a controller. In that role, Pete led financial oversight of various groups including Business Development, Sales and Marketing.  During this time Pete was also a member of the team responsible for the acquisition of Centocor.

He earned his Bachelor of Science degree in Accounting from Villanova University, Villanova, Pennsylvania, and is a licensed certified Public Accountant (CPA) and Certified Management Accountant (CMA).

Pete Batesko

Vice President, Group Finance, Pharmaceuticals

ELIZABETH BLACKWOOD

VICE PRESIDENT AND CHIEF QUALITY OFFICER, PHARMACEUTICALS

Elizabeth Blackwood is Vice President, Chief Quality Officer, Pharmaceuticals. She is a member of the Pharmaceuticals Group Operating Committee (GOC) and the Johnson & Johnson Quality & Compliance Leadership Team. She assumed this role in January 2015.

In this role, Liz is responsible for setting quality strategy and leading the implementation of quality processes and systems to achieve world-class performance in the Pharmaceuticals sector.

Previously, Liz served as Vice President, Quality Systems & Strategy, where she led the development of a common set of Johnson & Johnson quality standards and the supporting Information Technology infrastructure. Liz’s guidance was critical to the successful deployment of these tools. Her purview also included Customer Logistics & Services Quality and Operations Readiness and Convergence.

Liz first joined Johnson & Johnson in 2000, and returned in 2012 after four years with GE Healthcare as Senior Vice President, Global Quality Assurance where she was responsible for establishing one global quality management system across more than 100 sites. Prior to joining GE Healthcare, she worked at LifeScan, Inc.; Ethicon Endo-Surgery, Inc.; Ethicon, Inc.; and Johnson & Johnson Corporate Quality & Compliance Services. Her last position at Johnson & Johnson before joining GE Healthcare was Worldwide Vice President, Quality, Regulatory and Medical Affairs, at LifeScan, Inc.

Liz holds an Associate of Science degree in manufacturing technology from Keene State College, Keene, New Hampshire, a Bachelor of Science degree in Mechanical Engineering from the University of Lowell, Lowell, Massachusetts, and a Master of Science degree in Management from Lesley College, Cambridge, Massachusetts. She also serves on the United States Food & Drug Administration Good Manufacturing Practices Advisory Committee and is a voting member of the International Organization for Standardization Technical Advisory Groups (ISO TAG) 176 Quality Systems Standards.

Elizabeth Blackwood

Vice President and Chief Quality Officer, Pharmaceuticals

VANESSA BROADHURST

COMPANY GROUP CHAIRMAN
GLOBAL COMMERCIAL STRATEGY ORGANIZATION

Vanessa Broadhurst is Company Group Chairman, Global Commercial Strategy Organization (GCSO) and is a member of the Pharmaceuticals Group Operating Committee.

Prior to being named to this role, Vanessa was President, Cardiovascular & Metabolism (CVM) and a member of the Janssen Americas Leadership Team, a role she has held since May 2017. She also provided strategic oversight of the full portfolio of Janssen medicines in Puerto Rico and Canada. 

Prior to her CVM role, Vanessa was General Manager for the Bone Health and Cardiovascular Business Unit at Amgen. Previously, she was responsible for the Inflammation and Cardiovascular Business Unit at Amgen.

Vanessa originally joined Janssen in 2005. As Worldwide Vice President, Anemia/Oncology Supportive Care, she developed the global strategy for the franchise and drove therapeutic area development and growth. She also served as President of Janssen Therapeutics and Vice President of the Cardiovascular and Institutional Franchise before becoming President, Internal Medicine.

Prior to joining Janssen, she was with Novartis in Switzerland, where she was Head of Global Gastrointestinal Marketing. Vanessa started her career at Abbott, where she assumed her first General Management role in 2001, leading the U.S. Anti-Infective and Gastroenterology Business Unit. While at Abbott, she spent more than nine years in Marketing, Sales and Operational roles of increasing responsibility.

Vanessa is widely respected for her strategic insight and market acumen, as well as her commitment to talent development and diversity & inclusion. During her time with Janssen, she has served as Janssen America’s Sponsor of the African-American Leadership Council (AALC), MBA (ECLDP) Development Program and Culture Initiative, as well as former Executive Sponsor of the Woman’s Leadership Initiative (WLI). In 2018, Vanessa was named Woman of Excellence and Healthcare Champion of the Year by the National Association for Female Executives (NAFE).

Vanessa earned an MBA degree from the University of Michigan, where she was a Consortium for Graduate Study in Management Fellow, and a BA degree from the University of Colorado.

Vanessa Broadhurst

COMPANY GROUP CHAIRMAN
GLOBAL COMMERCIAL STRATEGY ORGANIZATION

Remo Colarusso is Vice President, Janssen Supply Chain (JSC) at Johnson & Johnson. In this capacity, Remo is responsible for the global manufacturing and supply management of all J&J pharmaceutical brands. He is a member of the Pharmaceutical Global Operating Committee (GOC) and the Johnson & Johnson Supply Chain (JJSC) Leadership Team.

Remo has more than 30 years of biotech and pharmaceutical experience with Johnson & Johnson in the areas of manufacturing, pharmaceutical development, planning, strategy, engineering, project management and process improvement (Lean/Six Sigma). Over the course of his career at Johnson & Johnson, he has held a variety of diverse, strategic leadership roles in the Pharmaceuticals (Janssen) sector, including Vice President, Manufacturing and Technical Operations (MTO), Vice President of Pharmaceutical Development & Manufacturing Sciences (PDMS) in the Research & Development Operations organization, and Vice-President, Product Management, where he was responsible for planning, new product introduction and product lifecycle management. Prior to joining Johnson & Johnson, Remo held roles in engineering at JM Huber Corporation and in process development at the Colgate Palmolive Company. 

Over the course of his distinguished career, Remo has been recognized for his tireless commitment to driving supply chain innovation and continuous improvement to deliver maximum value for customers and patients. Personally, he is a strong advocate for diversity and inclusion and focuses a lot of his time mentoring the next generation of industry leaders.

Remo is an active member of numerous organizations designed to support the leadership development and advancement of our industry. He is an active member in the Global Pharmaceutical Manufacturing Leaders Forum Committee of the International Society of Pharmaceutical Engineers (ISPE) and a member of the Pharmaceutical Manufacturers Forum with other supply chain senior leaders from across the pharmaceutical industry.  He also participates in the National Association of Manufacturers to further manufacturing excellence in the United States.

Remo holds a Bachelor of Science in Chemical Engineering and an MBA in Operations Research, both from Rutgers University.

Remo Colarusso

Vice President
Janssen Supply Chain

LINDA FEDOW

GLOBAL LEAD, PHARMACEUTICALS COMMUNICATION & PUBLIC AFFAIRS

Linda Fedow is Global Lead, Pharmaceuticals Communication & Public Affairs. She assumed this position in May 2012.

In this role, Linda is responsible for building the equity and reputation of Janssen as a leading global pharmaceuticals business and has accountability for the internal and external communication teams supporting Janssen around the world. She is a member of the Pharmaceuticals Group Operating Committee (GOC) and the Corporate Communication Leadership Team.

Prior to assuming her current role, Linda served as Vice President, Communication & Public Affairs, the Americas, in the Pharmaceuticals Group. As a member of the North America Leadership Team, she was responsible for developing communication and public affairs strategies to support the commercial objectives of the Janssen businesses in the United States, Latin America and Canada.

Previously, Linda was Vice President, Group Communications for the Comprehensive Care Group and served on its Group Operating Committee. In that role, she had dual responsibility, also serving as the global communication leader for the Ortho-Clinical Diagnostics franchise.

Linda joined the Johnson & Johnson Family of Companies in 1997 from a major international public relations agency, where she was responsible for marketing communications and wellness management strategies for consumer, healthcare, and food and beverage products. During her career at Johnson & Johnson, she has had regional and global accountabilities for the communication function within a number of operating companies and franchises, including women's health, central nervous system, analgesia, biopharmaceuticals and internal medicine.

Linda holds Bachelor of Science and Master of Arts degrees in Biology from the City University of New York.

Linda Fedow

Global Lead, Pharmaceuticals Communication & Public Affairs

ELIZABETH FORMINARD

General Counsel
Pharmaceuticals

Liz Forminard is General Counsel, Pharmaceuticals and is responsible for legal matters relating to the Pharmaceuticals Group globally. In addition, the Legal group providing support to Johnson & Johnson Global External Innovation also reports into Liz, and she will continue to play a leadership role in our external engagement with key corporate governance stakeholder organizations. 

Most recently Liz served as Worldwide Vice President, Corporate Governance and led the Office of the Corporate Secretary and the Enterprise Governance and Policy Group. She also served as General Counsel of the Global Supply Chain and Procurement organizations. As WW VP, Corporate Governance, Liz worked closely with our Chairman and CEO, the Executive Committee and our Board of Directors on corporate governance matters across the Enterprise. She also led the work to transform Johnson & Johnson’s external sustainability reporting in our Health for Humanity Report.

In her prior roles as a member of the Law Department Executive Committee, Liz was General Counsel, Consumer Group, with global responsibility for legal matters across Johnson & Johnson’s Consumer companies and oversaw legal support for the Global Supply Chain and Procurement organizations. Liz also previously served as General Counsel, Medical Devices & Diagnostics Group. 

Since joining Johnson & Johnson in 2006, Liz has served as Vice President Health Care Compliance, Medical Devices & Diagnostics; Worldwide Vice President Law at Ethicon; and Vice President Law for the Johnson & Johnson Consumer Healthcare Global Business Unit.

Before joining Johnson & Johnson, Liz developed extensive regulatory legal experience as an associate at the law firm Weil, Gotshal & Manges, and in the United States and Asia-Pacific legal operations of Pfizer Consumer Healthcare.

Liz holds a B.A. degree from Cornell University and a Juris Doctor (J.D.) degree from the University of Pennsylvania School of Law.

Elizabeth Forminard

General Counsel
Pharmaceuticals

JANE GRIFFITHS

GLOBAL HEAD, ACTELION

Jane Griffiths, Ph.D., is the Global Head of Actelion. She was named to this role in June 2017. Prior to this, Jane served as Company Group Chairman, Janssen Europe, Middle East and Africa (EMEA), providing strategic leadership, focusing on growth and building a sustainable business through people development and recruitment, and building trust and transparency both internally and externally.

In this role with Actelion, Jane will lead the successful integration of Actelion talent and capabilities into Janssen and Johnson & Johnson. She will chair the Actelion global leadership team, which will include Commercial, Medical Affairs, R&D, Supply Chain and all functional areas. With full, end-to-end P&L ownership, Jane will have responsibility for developing long-term strategic plans to maximize the growth of Actelion’s pulmonary arterial hypertension (PAH) medicines. She will play a key leadership role in the development and execution of Actelion’s portfolio and pipeline in partnership with R&D. And, she will lead the creation and delivery of commercial plans for the Actelion portfolio, ensuring profitable growth.

Under Jane’s leadership, Janssen EMEA achieved many noteworthy accomplishments, including the creation of Aspire, a program designed to drive the business to become a more outcomes-led organization; the establishment of the HEMAR and Real World Evidence teams; and the development and rollout of the customer-facing i-Connect system, improving metrics on activity and results.

Prior to leading Janssen EMEA, Jane was responsible for the EMEA Market Access unit. She has also served as International Vice President for Janssen-Cilag Northern Europe; Vice President, EMEA Biopharmaceuticals; and Managing Director, Ortho Biotech UK & Ireland.

An outspoken and passionate advocate for gender diversity, corporate social responsibility and sustainability, Jane has worked tirelessly to integrate these values throughout the organization. She will maintain her position as Chair of the Johnson & Johnson Corporate Citizenship Trust. Jane also believes strongly in improving the reputation of the pharmaceutical industry and has chaired the European Federation of Pharmaceutical Industries and Associations (EFPIA) executive committee, providing strong leadership on topics such as pricing, access and transparency of transfers of value to healthcare professionals.

Before her transition to general management, she held various positions of increasing responsibility in Sales, Marketing and R&D. Jane began her career with Johnson & Johnson in 1982 after earning her Ph.D. in Plant Biochemistry from the University of Aberystwyth, UK.

Jane Griffiths, Ph.D.

Global Head, Actelion

STEF HEYLEN, M.D.

CHIEF OPERATING OFFICER, DEVELOPMENT
JANSSEN RESEARCH & DEVELOPMENT

As Chief Operating Officer, Development, Janssen R&D, Stef Heylen, M.D., leads Development Management, Operations and Analytics. In addition, he is responsible for the Beerse campus as Managing Director, Janssen Pharmaceutica NV Belgium. In his global role, he oversees the development process overall, as well as essential analytical capabilities (portfolio, statistics, clinical operations), and is accountable for operationalizing and managing the extensive development portfolio.

During his career with Johnson & Johnson (J&J), Stef served with the Johnson & Johnson Innovation Program Office supporting the Johnson & Johnson Chief Scientific Officer in driving meaningful innovation and leveraging innovation capabilities across all sectors of the enterprise. He also was Head of R&D and Chief Medical Officer for Janssen Alzheimer Immunotherapy R&D, LLC, and he developed and implemented an integrated Research and Early Development (RED) Neuroscience strategy for the Beerse, Belgium site as Chief Medical Officer, Johnson & Johnson Pharmaceutical R&D, RED EU. From 2003 to 2007, Stef served as Site Head, Vice President of Development and Chairman of the Development Management Committee for Tibotec, a company acquired by J&J in 2002. During his tenure, two of the company’s HIV medicines were granted accelerated approval.

Before joining Tibotec, Stef was Vice President, Development & Regulatory Affairs at Crucell in Leiden, the Netherlands, and held several senior positions within Janssen including Vice President, Global Regulatory Affairs and Pharmacovigilance, and Vice President, Medical Affairs for the Europe, Middle East and Asia (EMEA) region. He joined the Janssen Research Foundation in 1987 and led the global clinical development of one of the most successful Janssen antipsychotic medicines.

Stef obtained his M.D. at the University of Leuven, Belgium, and the Prince Leopold Institute for Tropical Medicine in Antwerp, Belgium. He is a 1993 recipient of the Dr. Paul Janssen Award for R&D.

Stef Heylen, M.D.

Chief Operating Officer, Development
Janssen Research & Development

MATHAI MAMMEN, M.D., PH.D.

GLOBAL HEAD
RESEARCH AND DEVELOPMENT

As Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, Mathai’s mission is to focus the energy of the best research and development teams in the world at the intersection of profound unmet medical need and actionable breakthroughs in science and technology to make medicines of unequivocal benefit for humanity.  The team works across a wide range of therapeutic areas and biological pathways. Janssen’s approach to medicines is patient-focused, agnostic to both source of the idea and the treatment modality.  The team is invested deeply in data sciences in every aspect of R&D.  Janssen R&D has fueled the growth of Janssen to be the largest pharmaceutical company in the United States, and the fourth largest in the world..

Prior to joining Janssen in June 2017, Mathai was Senior Vice President at Merck Research Laboratories, responsible for research in the areas of Cardiovascular, Metabolic and Renal Diseases, Oncology/Immuno-Oncology and Immunology. Jointly with his team, he initiated numerous new programs and progressed eight into early clinical development. Prior to Merck, Mathai led R&D at Theravance, a company he co-founded in the San Francisco Bay Area in 1997 based on his work at Harvard University. His talented team of 200 scientists nominated 31 development candidates in 17 years, created five approved products and created a pipeline containing many additional late development-stage compounds. In 2014, he and the Theravance Leadership Team separated Theravance into two publicly traded companies: Innoviva (INVA) and Theravance Biopharma (TBPH).

Mathai has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University's Department of Chemistry, working with George Whitesides. He received his BSc in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.

Mathai Mammen, M.D., Ph.D.

GLOBAL HEAD,
RESEARCH AND DEVELOPMENT

KRISTEN MULHOLLAND

HEAD OF HUMAN RESOURCES, GLOBAL PHARMACEUTICALS GROUP AND EXTERNAL INNOVATION

Kristen Mulholland is the Head of Human Resources, Global Pharmaceuticals Group and External Innovation at Johnson & Johnson with responsibility for the global talent, recruiting, diversity, compensation, benefits, employee relations, external innovation and all aspects of the human resources agenda for the Group.

Kristen has held several global HR Leadership positions since joining Johnson & Johnson in 2005. As Vice President, Human Resources, she led innovative approaches for driving cultural change, talent management and engagement across the global Ethicon Endo-Surgery franchise. She was then named Vice President, Global Performance & Development, with responsibility for leading the enterprise strategic direction for enhancing employee performance and professional development. As Vice President, Human Resources, Global Pharmaceuticals Research & Development (R&D), Kristen advanced the Janssen R&D talent agenda, with a specific focus on enhancing the diversity of scientific talent and strengthening global, end-to-end Therapeutic Area capabilities. Kristen led the development of an enterprise-wide approach for building and measuring innovation capabilities required of R&D leaders of the future.

Kristen more than 15 years of experience in consulting and the healthcare industry, having spent 10 years consulting with Ernst & Young as part of the Human Capital practice and seven years with Eli Lilly and Company in various Human Resources roles.

Kristen holds a bachelor’s degree in political economics and German from Tulane University in New Orleans, Louisiana and a master’s degree in organization development from Case Western Reserve in Cleveland, Ohio.

Kristen Mulholland

Head of Human Resources, Global Pharmaceuticals Group and External Innovation

AI HUA ONG

COMPANY GROUP CHAIRMAN, ASIA PACIFIC

Ai Hua Ong joined Johnson & Johnson more than 25 years with a desire to make a difference to the lives of patients. This passion continues today, in her role as Company Group Chairman for Janssen Asia Pacific, where she oversees operations that deliver pharmaceutical innovation in Australia, China, Hong Kong, India, Japan, Korea, New Zealand and Taiwan.

Based in her native Singapore, Ai Hua is known for her deep commitment to customers and patients, her strategic insights and global mindset. She is an active volunteer for charitable causes and a strong advocate for women in leadership.

In her previous role as President of One J&J Southeast Asia, Ai Hua was instrumental in the successful implementation of Johnson & Johnson’s first-ever one-company enterprise business model encompassing pharmaceuticals, consumer products and medical devices. She nurtured a business with strong growth and enhanced efficiency across 10 countries the Association of Southeast Asian Nations (ASEAN).

Ai Hua holds a Bachelor of Science in Microbiology and Biochemistry and an Master’s in Business Administration from the National University of Singapore. She began her career in 1991 as a product specialist with Johnson & Johnson Medical Singapore. Since then, she has held leadership roles across strategic marketing, sales management, and licensing and acquisition.

Ai Hua is a committed volunteer for charitable causes and acts as chair of J&J’s Asia Pacific Contributions Committee. She is also a council member of the Singapore Dover Park Hospice and serves on the Advisory Board of the Singapore Management University Lee Kong Chian School of Business.

Ai Hua Ong

Company Group Chairman
Asia Pacific

KRIS STERKENS

COMPANY GROUP CHAIRMAN,EUROPE, MIDDLE EAST, AND AFRICA

Since starting his career at Janssen in Belgium almost 30 years ago, Kris Sterkens has been part of many teams across EMEA, Asia Pacific, and the United States.

Moving on from his latest role as the Company Group Chairman of Janssen Asia Pacific, Kris was appointed Company Group Chairman of Europe, Middle East and Africa in June 2017. He was excited to return to his home country, Belgium, after spending over three years in Singapore since February 2014 for the Asia Pacific business.

Under Kris’ stewardship, Janssen Asia Pacific achieved notable milestones, including a return to growth in China and a successful business transformation in Japan. Kris also led teams in Korea, Australia, and New Zealand and successfully competed against new biosimilar entrant, in addition to achieving industry-leading growth in India. Throughout his career, Kris has demonstrated exceptional leadership and an ability to identify and develop talent. For instance, in Asia Pacific, he introduced Company Group Chairman’s Dialogue, a talent development programme which has engaged more than 100 emerging leaders.

Prior to that, Kris was leading the EMEA Strategy Organisation, alongside his role as Managing Director of the region’s Mid-Sized Markets. He was also the Managing Director for Janssen the Netherlands, the Benelux countries, and then Germany from 2007–2012.

Before his transition into General Management, Kris was Vice President, Finance and Chief Finance Officer (CFO) for Janssen EMEA.

Kris holds a Master’s degree in Applied Economics from the University of Antwerp, a Master's degree in Financial Management from the Flemish Institute of Management, and an MBA from the Solvay Business School in Brussels. Kris is fluent in Dutch, English, German, and French and has been a frequent speaker at business schools, medical and patient group events, and industry meetings.

Kris Sterkens

Company Group Chairman,
Europe, Middle East, and Africa

Richard Tillyer, Ph.D, is Global Head, Discovery, Product Development & Supply, Janssen Research and Development. In this role, he leads an integrated discovery, process development and clinical supply organization that comprises all modalities including small molecules, traditional and non-traditional single molecule biologics, and larger, more complex multicomponent biologics including RNA, viruses and cells.

Rich joined Janssen in 2018 from Merck & Co (MSD outside the United States), where he acquired extensive experience in all stages of drug discovery and product development across numerous therapeutic areas and modalities. During his 25-year tenure, he led large and varying aspects of Merck Research Labs, including Process Chemistry, Toxicology, Drug Metabolism and Pharmacokinetics, Formulation, Biologics and Vaccines Process Development, High Throughput Screening, Discovery Biology, Medicinal Chemistry, Computational Chemistry and various platform groups. Under his leadership, Rich’s teams contributed to the discovery and development of most major products introduced by Merck over the last two decades and significantly advanced the company’s current pipeline. He led or actively contributed to major strategic initiatives including large and small-scale mergers and R&D integrations (most notably, the integration of Schering-Plough announced in 2009).

Rich obtained his Ph.D. in Chemistry from the University of British Columbia, Canada, and a post-doctoral research fellowship in Chemistry from the University of Cambridge, UK. He has published more than 70 scientific articles and publications and he holds several patents.

Richard Tillyer, Ph.D.

Global Head
Discovery
Product Development & Supply
Janssen Research & Development

PATRICK VERHEYEN

GLOBAL HEAD, JANSSEN BUSINESS DEVELOPMENT

Patrick Verheyen is Global Head, Janssen Business Development. In this role, Patrick leads the business development organization to identify, execute, integrate and manage global licensing, mergers & acquisitions (M&A), divestiture and out-licensing deals for the Janssen Pharmaceutical Companies of Johnson & Johnson. Patrick assumed this role in April 2015.

Prior to this, Patrick helped design and launch Johnson & Johnson Innovation and was the Head of Johnson & Johnson Innovation, London. This Innovation strategy has delivered a robust early-stage portfolio and has helped earn Johnson & Johnson a reputation as a preferred partner with external innovators, entrepreneurs and academic institutions.

Patrick joined Johnson & Johnson in 1986 at Janssen Pharmaceuticals in Beerse, Belgium.  He has held several leadership roles within our Pharmaceuticals organization including Vice President, New Ventures, Pharmaceuticals, where he led an agile and diverse team who facilitated divestitures, established strategic collaborations and identified investments that provided Janssen with access to external innovation and early product flow.  Patrick also served as Vice President, M&A, where he facilitated strategic collaborations and acquisitions including Crucell, Elan and Cougar Biotechnology, and established spin-out companies, including Movetis.  Patrick has provided expertise on most of the major M&A deals in the biotech, specialty pharmaceutical and large capital space, and assessed various risk sharing and funding arrangements with Clinical Research Organizations, private equity groups and government institutions.

Before beginning his professional career, he studied bioengineering at the University of Leuven, Flanders, Belgium.

Patrick Verheyen

Global Head, Janssen Business Development

SCOTT WHITE

Company Group Chairman
North America Pharmaceuticals
Johnson & Johnson

Scott White is Company Group Chairman, North America, at the Janssen Pharmaceutical Companies of Johnson & Johnson. A member of the Pharmaceuticals Group Operating Committee, he is responsible for leading Janssen’s efforts to transform the health of people in the U.S. and Canada facing cancer, autoimmune disease, heart disease and diabetes, infectious diseases including HIV, pulmonary arterial hypertension, and serious mental illness.

In his 28-year career at Janssen, Scott has led some of our most significant businesses across multiple serious disease areas. He is a results-focused leader, widely respected for his strategic insight and commitment to developing high-performing, diverse teams.

As President, Janssen U.S. Immunology, Scott led Johnson & Johnson’s largest business, making a significant difference for people with debilitating autoimmune diseases through highly impactful medicines including REMICADE®, STELARA®, SIMPONI®, SIMPONI ARIA® and TREMFYA®, and innovative patient support and access programs. Prior to his Immunology role, Scott was President of Janssen U.S. Oncology. Under Scott’s leadership, Janssen launched two transformational cancer treatments, IMBRUVICA® for chronic lymphocytic leukemia and DARZALEX® for multiple myeloma, making Janssen Oncology one of the fastest growing oncology businesses in the U.S. Previously, Scott held the position of Vice President, Strategic Customer Group, serving all Janssen U.S. businesses, where he led contracting and account management. In this critical role, he served as the market access leader to ensure people who need our medicines have access to them.

Scott holds a Bachelor of Arts from Rutgers, The State University of New Jersey, where he double-majored in molecular biology and philosophy. He also received a Master of Business Administration from the University of Phoenix.

Scott White

Company Group Chairman
North America Pharmaceuticals
Johnson & Johnson